596 related articles for article (PubMed ID: 10470194)
1. Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse.
Molina R; Farrus B; Filella X; Jo J; Zanón G; Pahisa J; Latre M; Muñoz M; Ballesta AM
Anticancer Res; 1999; 19(4A):2557-62. PubMed ID: 10470194
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.
Molina R; Filella X; Alicarte J; Zanon G; Pahisa J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1035-41. PubMed ID: 12820344
[TBL] [Abstract][Full Text] [Related]
3. Serum c-erbB-2 protein in breast cancer patients.
Chearskul S; Sinlarat P; Bhothisuwan K; Churintrapun M; Ornrhebroi S; Klinsala N; Sungkabunchoo S
J Med Assoc Thai; 2000 Aug; 83(8):886-93. PubMed ID: 10998842
[TBL] [Abstract][Full Text] [Related]
4. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
Lumachi F; Basso SM; Brandes AA; Pagano D; Ermani M
Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
[TBL] [Abstract][Full Text] [Related]
5. Carcinoembryonic antigen: an invaluable marker for advanced breast cancer.
Pathak KA; Khanna R; Khanna HD; Khanna S; Gupta S; Khanna NN
J Postgrad Med; 1996; 42(3):68-71. PubMed ID: 9715319
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.
Yu H; Levesque MA; Clark GM; Diamandis EP
Clin Cancer Res; 1998 Jun; 4(6):1489-97. PubMed ID: 9626467
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer and neoadjuvant therapy: any predictive marker?
Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
[TBL] [Abstract][Full Text] [Related]
8. [Clinical value of CEA studies in patients with benign and malignant breast diseases with special reference to oncologic after care].
Kunze M; Voss P; Büttner HH; Stranz G; Strache RR
Zentralbl Gynakol; 1987; 109(24):1517-26. PubMed ID: 3442160
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
[TBL] [Abstract][Full Text] [Related]
10. Prognostic contributions of Helix pomatia and carcinoembryonic antigen staining using histochemical techniques in breast carcinomas.
Fukutomi T; Itabashi M; Tsugane S; Yamamoto H; Nanasawa T; Hirota T
Jpn J Clin Oncol; 1989 Jun; 19(2):127-34. PubMed ID: 2733166
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
12. [mRNA expression of CK19 and CEA in peripheral blood of patients with breast cancer detected by real-time quantitative PCR].
Zheng HY; Chen Q; Ye YB; Huang WW
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(32):2267-70. PubMed ID: 19087676
[TBL] [Abstract][Full Text] [Related]
13. The importance of prognostic factors in premenopausal women with breast cancer.
Finek J; Holubec L; Topolcan O; Elgrova L; Skalova A; Pecen L
Anticancer Res; 2007; 27(4A):1893-6. PubMed ID: 17649790
[TBL] [Abstract][Full Text] [Related]
14. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients.
Molina R; Jo J; Filella X; Zanón G; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM
Anticancer Res; 1999; 19(4A):2551-5. PubMed ID: 10470193
[TBL] [Abstract][Full Text] [Related]
15. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of an immunoradiometric assay for CA15-3 antigen associated with human mammary carcinomas: comparison with carcinoembryonic antigen.
Fujino N; Haga Y; Sakamoto K; Egami H; Kimura M; Nishimura R; Akagi M
Jpn J Clin Oncol; 1986 Dec; 16(4):335-46. PubMed ID: 3467106
[TBL] [Abstract][Full Text] [Related]
17. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
[TBL] [Abstract][Full Text] [Related]
18. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer.
Nakata B; Takashima T; Ogawa Y; Ishikawa T; Hirakawa K
Br J Cancer; 2004 Aug; 91(5):873-8. PubMed ID: 15280913
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of the estrogen and progesterone receptor content of primary breast cancers without skeletal or visceral metastasis with tumor marker MCA, CEA and CA 15-3 serum concentration at the time of surgery].
Seifert M; Wierrani F; Kubista E; Spona J
Gynakol Rundsch; 1991; 31 Suppl 2():397-8. PubMed ID: 1790992
[No Abstract] [Full Text] [Related]
20. Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis.
Ebeling FC; Schmitt UM; Untch M; Nagel D; Fateh-Moghadam A; Stieber P; Seidel D
Anticancer Res; 1999; 19(4A):2545-50. PubMed ID: 10470192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
